Significance of EGFR signaling pathway genetic alterations in radically resected non-small cell lung cancers from a Polish cohort. One institutional study

摘要: Abstract Purpose We evaluated the distribution and clinical impact of EGFR , KRAS HER2 copy number gains BRAF activating mutations in resected non-small cell lung cancers (NSCLCs) from 151 Polish patients. Materials methods Quantitative PCR DNA sequencing were used for evaluation mutational analysis, respectively. Results An increased CN was found 21.2% tumors, more commonly non-squamous histology ( P  = 0.029), larger size  = 0.004) those obtained women  = 0.040). gain observed 21.8% patients, frequently with lymph node metastases  = 0.048) stage IIIA disease  = 0.061). 29.3% not associated patients’ clinicopathological features. No found. mutation frequency associations characteristics did differ significantly previously described NSCLC patients Caucasian ethnicity. Strong existed between most analyzed alterations. In multivariate model, constituted an independent prognostic factor recurrence adenocarcinoma (HR 7.20; 95%CI 1.31–39.48;  = 0.023), while tended to indicate a shorter overall survival 4.85; 0.92–25.58;  = 0.062). Conclusions pathway genes alterations are frequent NSCLCs have potential outcome after curative tumor resection. Gene by quantitative provides comparable results enables assay standardization, yet optimal scoring system needs be developed.